Drug Profile

Mepivacaine controlled release - Heron Therapeutics

Alternative Names: APF112

Latest Information Update: 19 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator A.P. Pharma
Developer Heron Therapeutics
Class Local anaesthetics; Piperidines; Small molecules
Mechanism of Action Sodium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Suspended Postoperative pain

Most Recent Events

13 Jan 2014 A.P. Pharma is now called Heron Therapeutics
27 May 2008 Phase II development is ongoing
12 Dec 2006 Mepivacaine controlled release is still available for partnering (http://www.appharma.com)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com